Copyright: ©Author(s) 2026.
World J Cardiol. Nov 26, 2026; 18(11): 124181
Published online Nov 26, 2026. doi: 10.4330/wjc.124181
Published online Nov 26, 2026. doi: 10.4330/wjc.124181
Figure 6 Xin-II significantly modulates protein levels in the peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 alpha signaling pathway to alleviate chronic heart failure.
A: The qPCR results for differentially expressed genes identified by transcriptomics; B-I: Protein expression levels of the peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 alpha signaling pathway (assessed by western blot). B-H show bar charts (with GAPDH as the internal control); I shows the protein band patterns for each protein. Quantification of protein expression levels via grayscale analysis. Data are presented as mean ± SEM. Statistical significance was determined by one-way analysis of variance followed by Tukey’s multiple comparisons test. aP < 0.05 (control vs model group); bP < 0.05 (model vs drug-treated group). PCK1: Phosphoenolpyruvate carboxykinase 1; PPAR: Peroxisome proliferator-activated receptor; HIF: Hypoxia-inducible factor; RISP: Rieske iron sulfur protein; STAT3: Signal transducer and activator of transcription 3.
- Citation: Liu XJ, Cong Y, Zheng R, Li M, Xiu Z, Hu PF, Wu GH, Lianhua CG, Wan Q. Xin-II shows cardioprotective effects in a rat model of chronic heart failure: An integrated network pharmacology and transcriptomic. World J Cardiol 2026; 18(11): 124181
- URL: https://www.wjgnet.com/1949-8462/full/v18/i11/124181.htm
- DOI: https://dx.doi.org/10.4330/wjc.124181